Abbott CEO Robert Ford called cancer testing a "critically important market" that the firm has made a priority to move into.

NEW YORK – The US Food and Drug Administration granted 510(k) marketing clearances in October to Becton Dickinson, Diasorin, Visby Medical, and others for pathogen detection assays and other in vitro ...

The agency would down-classify nucleic acid-based tests for use with a corresponding approved therapy product to Class II devices from Class III.

InnotiveDx's UTI diagnostic technology provides bacterial identification and antimicrobial susceptibility test results in less than 60 minutes.

Last week, readers were most interested in a story about a proposed acquisition by Abbott of Exact Sciences that would launch Abbott into the cancer testing space.

The pre-Series A funding round was led by Spectrum Impact with participation from the founders and existing investors including Vijay Alreja Family Office.

NEW YORK — Clinical informatics firm Ovation.io has partnered with PrecisionLife to develop a test that can identify individuals likely to respond to glucagon-like peptide-1 receptor agonist (GLP-1) ...

NEW YORK – Agilent Technologies said after the close of the market Monday that its fiscal fourth quarter revenues grew 9 percent year over year. For the three months ended Oct. 31, the Santa Clara, ...

A slew of new studies and reports suggest that new molecular approaches may soon help reduce the global burden of tuberculosis.

With the permit, St. Louis-based C2N can offer its PrecivityAD2 and PrecivityAD Alzheimer's blood tests to patients in New York state.